Core Insights - Preclinical data supports SLS009 as a promising treatment for T-cell prolymphocytic leukemia (T-PLL), both as a monotherapy and in combination with venetoclax [1][2][3] Group 1: Efficacy of SLS009 - SLS009 demonstrated significant single-agent activity and improved overall survival in a patient-derived xenograft model of relapsed/refractory T-PLL, with survival times of 7.4 weeks for SLS009 monotherapy and 7.9 weeks for the combination with venetoclax, compared to 4.4 weeks for venetoclax alone [2][3] - The combination of SLS009 and venetoclax was well tolerated, indicating a favorable safety profile [2][3] Group 2: Research Presentation - The findings will be presented at the European Society for Medical Oncology (ESMO) Congress 2025, scheduled for October 17-21, 2025, in Berlin, Germany [1][4] - The poster presentation is titled "CDK9 Inhibition Enhances Venetoclax Activity and Prolongs Survival in a T-PLL Patient-Derived Xenograft Model" [4] Group 3: Company Overview - SELLAS Life Sciences Group, Inc. is focused on developing novel therapies for various cancer indications, with SLS009 being a key candidate as a differentiated small molecule CDK9 inhibitor [5][6] - The company also has a lead product candidate, GPS, which targets the WT1 protein and has potential applications in multiple hematologic malignancies and solid tumors [5]

Core Insights - SLS009 (tambiciclib) shows potential in overcoming resistance to the azacitidine-venetoclax regimen in TP53 mutated Acute Myeloid Leukemia (AML) cells, with promising preclinical efficacy data presented at the AACR conference [1][2][3] Company Overview - SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on developing novel therapies for various cancer indications, with SLS009 being a key candidate [7] Preclinical Findings - SLS009, a selective CDK9 inhibitor, can induce apoptosis in TP53 mutated AML cells by targeting proteins like MCL-1 and survivin, achieving up to 97% reduction in leukemia cell populations when combined with azacitidine-venetoclax, and up to 80% as a monotherapy [2][3] - Immunoblot analysis indicates near-complete removal of targeted proteins within 8 hours of SLS009 exposure [2] Clinical Trial Progress - SLS009 is currently in Phase 2 clinical trials for relapsed or refractory AML, showing a median overall survival (mOS) of 8.8 months for all patients and 8.9 months for AML myelodysplasia-related changes (MRC) patients, significantly exceeding the historical benchmark of 2.5 months [3][6] - Response rates among patients with specific mutations include 67% for ASXL1, 60% for RUNX1, and 33% for TP53 [3] Expert Commentary - Experts highlight the significance of SLS009 in addressing the unmet needs of TP53 mutated AML, which has poor outcomes even with existing therapies [4]